Hamburg, Germany, 31 August 2013 - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced a capital increase against cash contribution by issuing 11,818,613 new shares to Biotechnology Value Fund, L.P. and other affiliates of the US biotech specialist investment firm, BVF Partners L.P. ('BVF'), San Francisco. Shareholders' subscription rights will be excluded. The price is EUR 2.55 per share. This involves a discount of approximately 3% to the closing auction price of the share on 27 August 2013, the day prior to the day of the Management Board resolution.
With the registration of the capital increase in the commercial register, the registered share capital of the Company will increase by nearly 10% to EUR 130,365,452.00. In a simultaneous transaction, BVF also purchased an option from TVM Capital Life Science ('TVM') granting BVF the right to acquire an additional 11,818,612 shares of Evotec at EUR 4.00 per share within the next 30 months. Should this option be exercised in full, BVF will have a total shareholding in Evotec of over 18%.
Revenue guidance of the Company remains unchanged. Given the capital inflow, Evotec increases its cash guidance to >EUR 90 m by the end of 2013.
Contact Evotec AG: Dr Werner Lanthaler, Chief Executive Officer, Phone: +49.(0)40.56081-242, werner.lanthaler@evotec.com